Navigation Links
Vaccine adjuvant uses host DNA to boost pathogen recognition

Aluminum salts, or alum, have been injected into billions of people as an adjuvant to make vaccines more effective. No one knows, however, how they boost the immune response. In the March 19, 2013, issue of the Proceedings of the National Academy of Sciences researchers at National Jewish Health continue unraveling the mystery of adjuvants with a report that host DNA coats the alum adjuvant and induces two crucial cells to interact twice as long during the initial stimulation of the adaptive immune system.

"Alum makes T cells take a longer look at the antigen, which produces a better immune response," said Philippa Marrack, PhD, senior author and professor of immunology at National Jewish Health. "Understanding how adjuvants work could help us make more effective vaccines. That is very important. Vaccines have saved millions of lives and been among the greatest advances in medical history."

Live vaccines, containing weakened forms of an infectious organism, generally work fine by themselves. But vaccines containing dead organisms (inactivated vaccines) or pieces of the infectious organisms or their toxins (acellular or recombinant vaccines) generally need adjuvants to boost their effectiveness. Aluminum salts, known as alum, are the only adjuvant approved for use in the United States for routine preventive vaccines.

Adjuvants were first discovered as the result of empirical experiments with tetanus early in the 20th century. They have been widely used in many vaccines since the 1940s, including the Diphtheria/Tetanus/Pertussis (DtaP), Hepatitis, Haemophilus influenzae (Hib), typhoid and some flu vaccines. No one fully understands why adjuvants boost the effectiveness of nonliving vaccines.

Recently a Belgian team showed that DNA is involved in the adjuvant effect. When they administered a vaccine with adjuvant and DNase, an enzyme that digests DNA, the vaccine was less effective. The National Jewish Health team built on those findings to reveal the role that DNA plays.

The National Jewish Health team had previously shown that the process starts with a series of events similar to those that initiate responses to bacterial infections. Neutrophils, and other early responders in the immune system, flood into a site of potential infection, attack the foreign agent, in this case the alum vaccine, then quickly die in massive numbers.

Upon death the neutrophils release large amounts of DNA, which uncoils from its chromatin spools and acts somewhat like a net to entangle the foreign agent. Other cells then engulf the DNA-alum-vaccine complex. These antigen-presenting cells display small fragments of the vaccine on their surfaces for T-cells to recognize. T-cells drive the adaptive immune response, the one that recognizes and attacks the specific infectious agent, as opposed to the more general innate immune response.

T-cells are also the basis for effective vaccines. Some T-cells, and the B-cells stimulated by the T-cells, transform into memory cells once the infection has been cleared. Those memory cells help mount a quicker and stronger immune response if they see that organism again.

The National Jewish Health team showed that the DNA coating the adjuvant doubles the time that the T-cell engages the vaccine fragment on the surface of the antigen-presenting cell. When they added DNase to digest DNA, the T-cell engaged the vaccine fragment half as long, and the vaccine was less effective. Several of the findings were made possible by an innovative use of multi-photon microscopy to film the interaction of T-cells and antigen-presenting cells.

"The DNA makes the antigen-presenting cell stickier," said Amy McKee, PhD, Instructor at the University of Colorado, and lead author of the paper. "We believe that extended engagement provides a stronger signal to the T-cell, which makes the immune response more robust."

The researchers are not sure exactly what makes the antigen-presenting cell 'stickier.' When that an antigen-presenting cell engulfs free-floating DNA, the researchers believe it recognizes that something is amiss (DNA should not normally be floating around outside an intact cell nucleus) and becomes more activated. It may respond with an additional co-receptor to engage the T-cell or release a molecule that stimulates the T-cell. The researchers are now working to understand that process.


Contact: William Allstetter
National Jewish Health

Related biology news :

1. Cleverly designed vaccine blocks H5 avian influenza in models
2. HPV vaccine trends point to failures in patient education, vaccine programs
3. Cancer vaccines self-sabotage, channel immune attack to injection site
4. Human trials for Streptococcus A vaccine
5. Novel aptamer boosts T cell-based immune response to therapeutic vaccines
6. Designer bacteria may lead to better vaccines
7. UMMS experts seek better flu vaccines
8. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
9. Vaccine offers promise as post-surgery treatment for pancreatic cancer patients
10. Texas Biomed files patent for a novel HIV vaccine strategy
11. RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
Post Your Comments:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
Breaking Biology Technology: